Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SRPT

Sarepta Therapeutics Inc

Nov 30 • 04:00PM ET

81.28

Dollar change +0.88
Percentage change 1.09	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.83	Insider Own	5.70%	Shs Outstand	93.55M	Perf Week	-2.97%
Market Cap	7.60B	Forward P/E	31.73	EPS next Y	2.56	Insider Trans	2.47%	Shs Float	88.21M	Perf Month	20.75%
Income	-690.88M	PEG	-	EPS next Q	-0.28	Inst Own	88.31%	Short Float / Ratio	4.82% / 2.83	Perf Quarter	-32.83%
Sales	1.10B	P/S	6.88	EPS this Y	15.52%	Inst Trans	6.35%	Short Interest	4.25M	Perf Half Y	-34.60%
Book/sh	8.17	P/B	9.95	EPS next Y	137.76%	ROA	-22.05%	Target Price	139.22	Perf Year	-31.19%
Cash/sh	18.53	P/C	4.39	EPS next 5Y	-	ROE	-115.61%	52W Range	55.25 - 159.89	Perf YTD	-37.27%
Dividend	-	P/FCF	-	EPS past 5Y	-56.35%	ROI	-32.35%	52W High	-49.17%	Beta	1.01
Dividend %	-	Quick Ratio	4.90	Sales past 5Y	45.19%	Gross Margin	83.66%	52W Low	47.11%	ATR	4.00
Employees	1162	Current Ratio	5.44	Sales Q/Q	44.10%	Oper. Margin	-36.13%	RSI (14)	36.77	Volatility	2.64% 4.26%
Optionable	Yes	Debt/Eq	1.79	EPS Q/Q	84.34%	Profit Margin	-62.52%	Rel Volume	0.84	Prev Close	80.40
Shortable	Yes	LT Debt/Eq	1.79	Earnings	Nov 01 AMC	Payout	-	Avg Volume	1.50M	Price	81.28
Recom	1.60	SMA20	-0.03%	SMA50	-20.22%	SMA200	-31.44%	Volume	1,269,515	Change	1.09%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line	$139
Apr-26-23	Initiated	SMBC Nikko	Outperform	$185
Apr-04-23	Initiated	Citigroup	Buy	$179
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$141 → $187
Dec-22-22	Reiterated	BTIG Research	Buy	$125 → $160
Dec-16-22	Upgrade	UBS	Neutral → Buy	$100 → $158
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$140
Jan-05-22	Reiterated	Needham	Buy	$157 → $150
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform	$125
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight	$130
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral	$92 → $87
Jun-15-21	Initiated	BTIG Research	Buy	$110
Apr-26-21	Resumed	Credit Suisse	Neutral	$72
Jan-12-21	Downgrade	Citigroup	Buy → Neutral	$215 → $108
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Today 06:34PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 82.64%: Read This Before Placing a Bet (Zacks)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-24-23 10:26AM	13 Stocks Insiders are Buying Now (Insider Monkey)
Nov-18-23 06:49AM	3 Monster Stocks in the Making (Motley Fool)
06:35AM	Loading…
Nov-16-23 06:35AM	3 Stocks Youll Regret Not Buying Soon: November 2023 (InvestorPlace)
Nov-13-23 09:55AM	Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now (Zacks)
07:57AM	Insiders Load Up on These 2 Strong Buy Stocks Heres Why You Should Pay Attention (TipRanks)
Nov-10-23 12:58AM	BioMarin gains on report Elliott has a stake: Insider trades & hedge funds weekly (Investing.com)
Nov-09-23 10:00AM	Is Sarepta Therapeutics Stock a Bad-News Buy? (Motley Fool)
Nov-08-23 10:15AM	1 Gene Therapy Stock to Buy and Hold for the Long Haul (Motley Fool)
Nov-07-23 11:23PM	Here's What Bronte Capital Calls Sarepta Risk in the Context of Sarepta Therapeutics (SRPT) (Insider Monkey)
Nov-02-23 06:25PM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:18PM	Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat (Zacks)
08:30AM	Sarepta Therapeutics to Present at the UBS Biopharma Conference (Business Wire)
12:00AM	Loading…
12:00AM	Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-01-23 05:03PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +13.68%
04:29PM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
04:05PM	Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
Oct-31-23 07:02PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -37.47%
04:19PM	Nvidia, Caterpillar, Sarepta: Trending Tickers (Yahoo Finance Video)
04:07PM	Sarepta Crashes 37% After Its Gene Therapy Flops Its Biggest-Ever Test (Investor's Business Daily)
03:03PM	Sarepta Therapeutics Stock Dives After New Gene Therapy Data (The Wall Street Journal)
11:52AM	Why Sarepta Therapeutics Stock Is Crashing Today (Motley Fool)
10:26AM	Sarepta Stock Sinks 43% on Uncertain Future for Its Gene Therapy (Barrons.com)
10:21AM	Morning Brew: Mixed Reviews for Apple's New Macs, Arista Networks Soars, and Sarepta Therapeutics (GuruFocus.com)
09:38AM	Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today? (InvestorPlace)
09:19AM	Sarepta Therapeutics Shares Dive After New Gene Therapy Data (The Wall Street Journal)
08:01AM	Sarepta Stock Sinks on Mixed Gene Therapy Results (Barrons.com)
07:51AM	Gene Therapy for Kids Deadly Muscle Disease Fails to Reach Trial Goal (Bloomberg)
07:19AM	Loading…
07:19AM	Sarepta Therapeutics Stock Dives After Unveiling Mixed Results For Its First Gene Therapy (Investor's Business Daily)
Oct-30-23 04:28PM	UPDATE 2-Sarepta's muscular dystrophy therapy fails to meet main goal in late-stage trial (Reuters)
04:10PM	Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial (Reuters)
04:01PM	Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy (Business Wire)
Oct-26-23 10:02AM	Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 10:02AM	Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) -5.45%
08:30AM	Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results (Business Wire)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-17-23 11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks)
11:30AM	AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review (Zacks)
Oct-09-23 10:41AM	Sarepta Therapeutics Stock Showing Rising Relative Strength (Investor's Business Daily)
09:55AM	Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.6%: Here's is How to Trade (Zacks)
09:49AM	Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody (Zacks)
Sep-29-23 06:30PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-15-23 12:50PM	Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? (Investor's Business Daily)
08:37AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Sep-14-23 10:07AM	2 Top Growth Stocks to Buy With $500 (Motley Fool)
Sep-07-23 09:00AM	Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year (Business Wire)
Sep-05-23 08:30AM	Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Sep-01-23 11:31AM	Sarepta Therapeutics (SRPT) Up 12.7% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-31-23 06:15PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks)
08:40AM	Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test (PR Newswire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 01:00PM	Is Sarepta Therapeutics Stock a Top Growth Vehicle? (Motley Fool)
Aug-22-23 10:00AM	3 Revolutionary Stocks I'd Buy Right Now Without Hesitation (Motley Fool)
Aug-13-23 08:08AM	Sarepta Therapeutics' Michael Chambers Acquires 19% More Stock (Simply Wall St.)
Aug-04-23 03:22PM	FDA-approved gene therapy invented at Nationwide Children's carries a $3.2M price tag. Here's why. (American City Business Journals)
Aug-03-23 11:28AM	Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss (Zacks)
Aug-02-23 09:00PM	Sarepta Therapeutics (SRPT) Q2 2023 Earnings Call Transcript (Motley Fool)
06:15PM	Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:08PM	Sarepta Therapeutics: Q2 Earnings Snapshot (AP Finance)
04:05PM	Sarepta Therapeutics Announces Second Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
Jul-31-23 06:08PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-27-23 07:30AM	2 Biotech Growth Stocks I'd Buy Right Now (Motley Fool)
Jul-26-23 10:02AM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:30AM	Sarepta Therapeutics to Announce Second Quarter 2023 Financial Results (Business Wire)
Jul-25-23 10:01AM	Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-16-23 08:20AM	Sarepta Therapeutics Insider Ups Holding By 47% During Year (Simply Wall St.)
Jul-12-23 05:33PM	3 Biotech Stocks to Sell Before They Damage Your Portfolio (InvestorPlace)
Jul-05-23 08:30AM	Sarepta Therapeutics Announces Sale of Priority Review Voucher for $102 million (Business Wire)
Jul-03-23 08:30AM	Sarepta Therapeutics to Present at Cowen's 2nd Annual RNA Therapeutics Summit (Business Wire)
Jun-30-23 06:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:45AM	Sarepta Therapeutics' Stock Is Down 14% in 1 Month, So Why Does Wall Street Expect It to Rise 65%? (Motley Fool)
Jun-29-23 09:02AM	Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates (Zacks)
Jun-23-23 04:07PM	Sarepta Plummets Despite Winning FDA Nod For $3.2 Million Gene Therapy (Investor's Business Daily) -7.93%
Jun-22-23 05:17PM	The Price of First Gene Therapy for Muscular Dystrophy: $3.2 Million (The Wall Street Journal)
04:02PM	Sarepta Stock Yo-Yoes After Winning Highly Anticipated Gene Therapy Nod (Investor's Business Daily)
03:02PM	First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids (AP Finance)
02:24PM	Sarepta Wins FDA Approval For Highly Anticipated Gene Therapy (Investor's Business Daily)
02:23PM	First Gene Therapy for Muscular Dystrophy Approved (The Wall Street Journal)
02:08PM	UPDATE 4-US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids (Reuters)
02:02PM	Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy (Business Wire)
Jun-17-23 09:45AM	Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jun-12-23 09:30AM	3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon (InvestorPlace)
Jun-08-23 11:30AM	Mirati (MRTX) Down 17.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-01-23 11:31AM	Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report? (Zacks)
10:04AM	15 Best Healthcare Stocks To Buy Now (Insider Monkey)
06:45AM	Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval? (Motley Fool)
May-31-23 06:16PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-24-23 04:04PM	Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy (Investor's Business Daily) -10.58%
01:53PM	Why Shares of Sarepta Therapeutics Are Dropping Wednesday (Motley Fool)
12:28PM	FDA Extends Review For Sarepta Therapeutics' Duchenne Gene Therapy By Couple Of Weeks (Benzinga)
09:53AM	2 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
08:24AM	UPDATE 2-FDA defers decision for Sarepta's gene therapy to June 22 from May 29 (Reuters)
08:07AM	FDA defers decision for Sarepta's gene therapy to June 22 (Reuters)
08:00AM	Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 (Business Wire)
May-16-23 03:42PM	Why These 3 Nasdaq Stocks Buckled Today (Motley Fool) -5.12%
08:30AM	Gene-Therapy Investors Have a Powerful Ally: Patients (The Wall Street Journal)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BEHRENS M KATHLEEN	Director	Nov 03	Option Exercise	29.03	15,000	435,450	174,993	Nov 06 08:00 AM
Barry Richard	Director	Nov 03	Buy	78.81	50,000	3,940,500	140,000	Nov 06 08:00 AM
INGRAM DOUGLAS S	President & CEO	Nov 03	Buy	79.36	25,225	2,001,800	390,307	Nov 06 08:00 AM
Chambers Michael Andrew	Director	Aug 14	Buy	109.47	9,979	1,092,429	246,996	Aug 15 08:00 AM
Chambers Michael Andrew	Director	Aug 11	Buy	108.05	23,686	2,559,272	237,017	Aug 14 08:00 AM
Chambers Michael Andrew	Director	Aug 10	Buy	106.15	34,867	3,701,067	213,331	Aug 11 07:40 AM
Wigzell Hans Lennart Rudolf	Director	Aug 04	Option Exercise	29.03	15,000	435,450	35,994	Aug 08 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Aug 04	Sale	106.72	15,000	1,600,800	20,994	Aug 08 08:00 PM
BEHRENS M KATHLEEN	Director	Dec 19	Option Exercise	34.92	20,000	698,400	158,470	Dec 21 09:05 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience